Zobrazeno 1 - 10
of 66
pro vyhledávání: '"Antonio Lazzaro"'
Autor:
Sara Fraticelli, Marco Lucioni, Giuseppe Neri, Deborah Marchiori, Caterina Cristinelli, Michele Merli, Rodolfo Monaco, Tiziana Borra, Antonio Lazzaro, Silvia Uccella, Luca Arcaini, Marco Paulli
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 9, p 7813 (2023)
Castleman disease (CD) is a rare lymphoproliferative disorder that includes various clinico-pathological subtypes. According to clinical course, CD is divided into unicentric CD (UCD) and multicentric CD (MCD). MCD is further distinguished based on t
Externí odkaz:
https://doaj.org/article/fcb9d223468343d891912f5513cc0ebf
Publikováno v:
Clinical Case Reports, Vol 9, Iss 6, Pp n/a-n/a (2021)
Abstract Patients with hematological cancer are at major risk of developing infectious complication. The prevention and treatment of COVID‐19 in these patients is challenging. This experience, with the limitation of a small number of patients, high
Externí odkaz:
https://doaj.org/article/3a42c992901d4b059491ea91573de487
Autor:
Stefano Sacchi, Luigi Marcheselli, Alessia Bari, Raffaella Marcheselli, Samantha Pozzi, Stefano Luminari, Marco Lombardo, Gabriele Buda, Antonio Lazzaro, Paolo G. Gobbi, Caterina Stelitano, Fortunato Morabito, Giovanni Quarta, Maura Brugiatelli
Publikováno v:
Haematologica, Vol 93, Iss 3 (2008)
Background Relatively little information is available on the incidence of secondary cancer in non-Hodgkin’s lymphoma. The aim of this long-term follow-up study was to determine the incidence, the time free of second tumors, and risk factors for dev
Externí odkaz:
https://doaj.org/article/deac9396fda34d4ab129ce1c706ef825
Autor:
Massimo Federico, Cesare Guglielmi, Stefano Luminari, Caterina Mammi, Luigi Marcheselli, Umberto Gianelli, Antonino Maiorana, Francesco Merli, Monica Bellei, Samantha Pozzi, Caterina Stelitano, Antonio Lazzaro, Paolo G. Gobbi, Luca Baldini, Stefania Bergantini, Vittorio Fregoni, Maura Brugiatelli
Publikováno v:
Haematologica, Vol 92, Iss 11 (2007)
Background and Objectives Although serum β2 microglobulin (β2 M) is an easy parameter to measure, and over-expressed in a large number of lymphoproliferative diseases, its prognostic value has been largely underestimated. The present study examined
Externí odkaz:
https://doaj.org/article/6179232d3f7444d794da0197d4fd5f56
Autor:
Fredrik H Schjesvold, Meletios-Athanasios Dimopoulos, Sosana Delimpasi, Pawel Robak, Daniel Coriu, Wojciech Legiec, Luděk Pour, Ivan Špička, Tamas Masszi, Vadim Doronin, Jiri Minarik, Galina Salogub, Yulia Alekseeva, Antonio Lazzaro, Vladimir Maisnar, Gábor Mikala, Laura Rosiñol, Anna Marina Liberati, Argiris Symeonidis, Victoria Moody, Marcus Thuresson, Catriona Byrne, Johan Harmenberg, Nicolaas A Bakker, Roman Hájek, Maria-Victoria Mateos, Paul G Richardson, Pieter Sonneveld, Fredrik Schjesvold, Anna Nikolayeva, Waldemar Tomczak, Ludek Pour, Ivan Spicka, Gabor Mikala, Laura Rosinol, Tatiana Konstantinova, Anargyros Symeonidis, Moshe Gatt, Arpad Illes, Haifaa Abdulhaq, Moez Dungarwalla, Sebastian Grosicki, Roman Hajek, Xavier Leleu, Alexander Myasnikov, Paul G. Richardson, Irit Avivi, Dries Deeren, Mercedes Gironella, Miguel Teodoro Hernandez-Garcia, Joaquin Martinez Lopez, Muriel Newinger-Porte, Paz Ribas, Olga Samoilova, Eric Voog, Mario Arnao-Herraiz, Estrella Carrillo-Cruz, Paolo Corradini, Jyothi Dodlapati, Miquel Granell Gorrochategui, Shang-Yi Huang, Matthew Jenner, Lionel Karlin, Jin Seok Kim, Agnieszka Kopacz, Nadezhda Medvedeva, Chang-Ki Min, Roberto Mina, Katrin Palk, Ho-Jin Shin, Sang Kyun Sohn, Jason Tache, Achilles Anagnostopoulos, Jose-Maria Arguiñano, Michele Cavo, Joanne Filicko, Margaret Garnes, Janusz Halka, Kathrin Herzog-Tzarfati, Natalia Ipatova, Kihyun Kim, Maria-Theresa Krauth, Irina Kryuchkova, Mihaela Cornelia Lazaroiu, Mario Luppi, Andrei Proydakov, Alessandro Rambaldi, Milda Rudzianskiene, Su-Peng Yeh, Maria Magdalena Alcalá-Peña, Adrian Alegre Amor, Hussain Alizadeh, Maurizio Bendandi, Gillian Brearton, Randall Brown, Jim Cavet, Najib Dally, Miklos Egyed, José Ángel Hernández-Rivas, Ain Kaare, Jean-Michel Karsenti, Janusz Kloczko, William Kreisle, Je-Jung Lee, Sigrid Machherndl-Spandl, Sudhir Manda, Ivan Moiseev, Jan Moreb, Zsolt Nagy, Santosh Nair, Albert Oriol-Rocafiguera, Michael Osswald, Paula Otero-Rodriguez, Valdas Peceliunas, Torben Plesner, Philippe Rey, Giuseppe Rossi, Don Stevens, Celia Suriu, Corrado Tarella, Anke Verlinden, Alain Zannetti
Publikováno v:
The Lancet Haematology, 9(2), e98-e110. Lancet Publishing Group
Digital.CSIC. Repositorio Institucional del CSIC
instname
Digital.CSIC. Repositorio Institucional del CSIC
instname
Background Melphalan flufenamide (melflufen), an alkylating peptide-drug conjugate, plus dexamethasone showed clinical activity and manageable safety in the phase 2 HORIZON study. We aimed to determine whether melflufen plus dexamethasone would provi
Autor:
Paola Tacchetti, Lucia Pantani, Francesca Patriarca, Maria Teresa Petrucci, Elena Zamagni, Luca Dozza, Monica Galli, Francesco Di Raimondo, Claudia Crippa, Mario Boccadoro, Simona Barbato, Patrizia Tosi, Franco Narni, Vittorio Montefusco, Nicoletta Testoni, Antonio Spadano, Carolina Terragna, Norbert Pescosta, Giulia Marzocchi, Claudia Cellini, Piero Galieni, Sonia Ronconi, Marco Gobbi, Lucio Catalano, Antonio Lazzaro, Giovanni De Sabbata, Clotilde Cangialosi, Fabrizio Ciambelli, Pellegrino Musto, Francesca Elice, Michele Cavo, Renato Fanin, Roberto Foa', Alessandro Rambaldi, Giuseppe Rossi, Pietro Leoni, Paolo Corradini, Giuseppe Torelli, Giuseppe Fioritoni, Sergio Cortelazzo, Giorgio Lambertenghi Deliliers, Giorgio La Nasa, Alfonso Zaccaria, Paolo De Fabritiis, Nicola Cascavilla, Alberto Bosi, Gianpietro Semenzato, Luigi Gugliotta, Filippo Gherlinzoni, Emanuele Angelucci, Massimo Fabrizio Martelli, Maria Concetta Petti, Giuseppe Leone, Angelo Michele Carella, Fabio Ciceri, Armando Santoro, Felicetto Ferrara, Francesco Nobile, Alfonso Maria D'Arco, Alessandro Levis, Luciano Guardigni, Andrea Gallamini, Pier Paolo Fattori, Sergio Morandi, Dino Amadori, Bruno Rotoli, Salvatore Mirto, Giorgio Paladini, Ruggero Mozzana, Graziella Pinotti, Francesco Rodeghiero, Nicola Cantore, Vincenzo Pavone, Enrico Maria Pogliani, Anna Marina Liberati, Ignazio Majolino, Sergio Amadori, Francesco Lauria, Massimo Aglietta, Giovanni Quarta, Sergio Storti, Fortunato Morabito, Silvana Franca Capalbo, Alessandro Massimo Gianni, Vincenzo Mettivier, Vittorio Rizzoli, Carlo Bernasconi, Giuseppe Visani, Michele Pizzuti, Giacinto La Verde, Giuseppe Avvisati, Maurizio Longinotti, Eugenio Gallo, Franco Dammacco, Domenico Russo, Andrea Bacigalupo, Caterina Musolino
Publikováno v:
The Lancet Haematology. 7:e861-e873
Background: The phase 3 GIMEMA-MMY-3006 trial, which compared bortezomib, thalidomide, and dexamethasone (VTD) combination therapy with thalidomide and dexamethasone (TD) as induction therapy before and consolidation therapy after double autologous h
Autor:
Philippe Moreau, Kevin W. Song, Anita Zahlten-Kumeli, James R. Berenson, Meletios A. Dimopoulos, A. Keith Stewart, Mei Huang, Antonio Lazzaro, Maria-Victoria Mateos, Katja Weisel
Publikováno v:
The Lancet Oncology. 19:953-964
Summary Background Twice a week carfilzomib at 27 mg/m 2 is approved for treatment of relapsed or refractory multiple myeloma. Phase 1/2 CHAMPION-1, the first study exploring once-weekly carfilzomib dosing, established the maximum tolerated dose at 7
Autor:
Catriona Byrne, Pieter Sonneveld, Daniel Coriu, Paul G. Richardson, Torbjörn Kullenburg, Maria-Victoria Mateos, Marcus Thuresson, Antonio Lazzaro, Johan Harmenberg, Haifaa Abdulhaq, Fredrik Schjesvold
Publikováno v:
Blood. 138:2732-2732
Background: Most pts with MM are older (median age at diagnosis: 69 y), have comorbidities (Engelhardt, et al. Haematologica. 2017;102:910), and often relapse. Thus, there is a high unmet need for novel, tolerable agents to treat RRMM. Melphalan fluf
Autor:
Pawef Robak, Victoria Moody, Gabor Mikala, Meletios-Athanasios Dimopoulos, Fredrik Schjesvold, Ivan Spicka, Luděk Pour, Yulia Alexeeva, Galina Salogub, Antonio Lazzaro, Tamás Masszi, Maria-Victoria Mateos, Paul G. Richardson, Vadim A Doronin, Sosana Delimpasi, Daniel Coriu, Catriona Byrne, Vladimir Maisnar, Marcus Thuresson, Wojciech Legiec, Johan Harmenberg, Pieter Sonneveld, Roman Hájek, Jiri Minarik
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S32
Background Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and thereby rapidly releases alkylating agents inside tumor cells. Accelerated approval in the United States of melflufen + dex for p
Autor:
Guido Cavaletti, Patrizia Tosi, Marina Martello, Monica Galli, Michele Cavo, Francesca Elice, Antonio Lazzaro, Maria Teresa Petrucci, Alessandro Gozzetti, Elena Zamagni, Annalisa Pezzi, Carolina Terragna, Lucia Pantani, Miriana Ruggieri, Antonio Palumbo, Paola Tacchetti, Luca Baldini, Jacopo Peccatori, Vittorio Montefusco, Serena Rocchi
Publikováno v:
American Journal of Hematology. 89:1085-1091
A subanalysis of the GIMEMA-MMY-3006 trial was performed to characterize treatment-emergent peripheral neuropathy (PN) in patients randomized to thalidomide-dexamethasone (TD) or bortezomib-TD (VTD) before and after double autologous transplantation